CHELMSFORD, Mass., Feb. 1, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has completed the previously announced sale of the company's Semiconductor Solutions Group business ...

Azenta shows strong organic growth, margin expansion, $1B+ asset value, rebounding sales multiples, and positive FY26 guidance. See why AZTA stock is a hold.

Shares of Azenta rose on Wednesday after the company's board of directors approved the repurchase of up to $250 million of common stock. Shares rose 5% to $37.23, though are down 20% year-to-date. The ...

Azenta Life Sciences, a key player in the life sciences industry, is poised for financial recovery with a robust Q2 performance and cost-cutting measures, making it an enticing investment opportunity.

BURLINGTON, Mass., Jan. 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has been selected as the technology provider by UK Biocentre as they expand their large-scale ...

CHELMSFORD, Mass, Jan. 24, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal 2022 first quarter earnings which ended on December 31, 2021 on Tuesday, February 8, 2022 after the ...

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here. A return of -0.72% ...

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market ...

BURLINGTON, Mass., July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a ...

As part of our SLAS Europe 2022 coverage, we spoke to Gerrit Gutzke and Michael Bussmann from Azenta Life Sciences about the products they offer for life sciences research and what the future looks ...

Azenta Life Sciences is a pharmaceutical company that specializes in developing and commercializing innovative therapies for the treatment of cancer. The company's lead product candidate is a novel ...

This authorization does not obligate Azenta to repurchase any specific dollar amount or number of shares, and repurchases may be commenced, suspended, modified, or discontinued at any time without ...